GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (OTCPK:ONPPF) » Definitions » EV-to-EBITDA

Oncopeptides AB (Oncopeptides AB) EV-to-EBITDA : -3.07 (As of Jun. 06, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Oncopeptides AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Oncopeptides AB's enterprise value is $68.52 Mil. Oncopeptides AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-22.31 Mil. Therefore, Oncopeptides AB's EV-to-EBITDA for today is -3.07.

The historical rank and industry rank for Oncopeptides AB's EV-to-EBITDA or its related term are showing as below:

ONPPF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.05   Med: -1.76   Max: 0.25
Current: -3.03

During the past 10 years, the highest EV-to-EBITDA of Oncopeptides AB was 0.25. The lowest was -6.05. And the median was -1.76.

ONPPF's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.15 vs ONPPF: -3.03

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-06), Oncopeptides AB's stock price is $0.265. Oncopeptides AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.184. Therefore, Oncopeptides AB's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Oncopeptides AB EV-to-EBITDA Historical Data

The historical data trend for Oncopeptides AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB EV-to-EBITDA Chart

Oncopeptides AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.33 -6.78 -0.20 -2.39 -2.79

Oncopeptides AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.40 -1.92 -2.52 -2.79 -2.53

Competitive Comparison of Oncopeptides AB's EV-to-EBITDA

For the Biotechnology subindustry, Oncopeptides AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncopeptides AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's EV-to-EBITDA falls into.



Oncopeptides AB EV-to-EBITDA Calculation

Oncopeptides AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=68.515/-22.312
=-3.07

Oncopeptides AB's current Enterprise Value is $68.52 Mil.
Oncopeptides AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncopeptides AB  (OTCPK:ONPPF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Oncopeptides AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.265/-0.184
=At Loss

Oncopeptides AB's share price for today is $0.265.
Oncopeptides AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.184.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Oncopeptides AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncopeptides AB (Oncopeptides AB) Business Description

Traded in Other Exchanges
Address
Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate melflufen (Ygalo), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.